About Spruce Bio
Spruce is committed to transforming the lives of patients living with endocrine and neurological disorders by developing and commercializing novel therapies where there is significant unmet medical need. Spruce’s product candidate, tildacerfont, is a CRF1 receptor antagonist currently in late-stage clinical trials in adult and pediatric patients with classic congenital adrenal hyperplasia (CAH) and polycystic ovary syndrome (PCOS). Spruce is collaborating with HMNC Brain Health to advance the development of tildacerfont as a personalized therapy option for the treatment of major depressive disorder (MDD).